Apollo Hospitals Enterprise Limited

rs,

LC008035 May 31, 2025 The Secretary, Bombay Stock Exchange Ltd (BSE) Phiroze Jheejheebhoy Towers, Dalal Street, Mumbai - 400 001. Scrip Code - 508869 ISIN INE437A01024 'G' Block The Secretary

10%

%) EBITDA(Post Ind AS) Margin Growth YoY(%) PAT Growth YoY(%) Healthcare Services 28,219 10% 6,862 24.3% 16% 3,851 13.6% 37% o C h t l a e H o l l o p A Offline PD ^ 20,844 17%

24.3%

st Ind AS) Margin Growth YoY(%) PAT Growth YoY(%) Healthcare Services 28,219 10% 6,862 24.3% 16% 3,851 13.6% 37% o C h t l a e H o l l o p A Offline PD ^ 20,844 17% 1,616 7.8%

16%

AS) Margin Growth YoY(%) PAT Growth YoY(%) Healthcare Services 28,219 10% 6,862 24.3% 16% 3,851 13.6% 37% o C h t l a e H o l l o p A Offline PD ^ 20,844 17% 1,616 7.8% 21%

13.6%

Growth YoY(%) PAT Growth YoY(%) Healthcare Services 28,219 10% 6,862 24.3% 16% 3,851 13.6% 37% o C h t l a e H o l l o p A Offline PD ^ 20,844 17% 1,616 7.8% 21% Online PD^ & 2

37%

YoY(%) PAT Growth YoY(%) Healthcare Services 28,219 10% 6,862 24.3% 16% 3,851 13.6% 37% o C h t l a e H o l l o p A Offline PD ^ 20,844 17% 1,616 7.8% 21% Online PD^ & 24|7

17%

10% 6,862 24.3% 16% 3,851 13.6% 37% o C h t l a e H o l l o p A Offline PD ^ 20,844 17% 1,616 7.8% 21% Online PD^ & 24|7 2,919 22% (1,253) Vs (1,219) in Q4F24 Total HealthCo

7.8%

24.3% 16% 3,851 13.6% 37% o C h t l a e H o l l o p A Offline PD ^ 20,844 17% 1,616 7.8% 21% Online PD^ & 24|7 2,919 22% (1,253) Vs (1,219) in Q4F24 Total HealthCo 23,763 17%

21%

16% 3,851 13.6% 37% o C h t l a e H o l l o p A Offline PD ^ 20,844 17% 1,616 7.8% 21% Online PD^ & 24|7 2,919 22% (1,253) Vs (1,219) in Q4F24 Total HealthCo 23,763 17% 363

22%

l a e H o l l o p A Offline PD ^ 20,844 17% 1,616 7.8% 21% Online PD^ & 24|7 2,919 22% (1,253) Vs (1,219) in Q4F24 Total HealthCo 23,763 17% 363 1.5% 88 0.4% AHLL 3,940 1

1.5%

Online PD^ & 24|7 2,919 22% (1,253) Vs (1,219) in Q4F24 Total HealthCo 23,763 17% 363 1.5% 88 0.4% AHLL 3,940 11% 472 12% 32% (43) Consolidated 55,922 13% 7,698 13.8% 20%

0.4%

& 24|7 2,919 22% (1,253) Vs (1,219) in Q4F24 Total HealthCo 23,763 17% 363 1.5% 88 0.4% AHLL 3,940 11% 472 12% 32% (43) Consolidated 55,922 13% 7,698 13.8% 20% 3,896 7

“Tel Telefax Email Website : www.apollohospitals.com : 044 - 2829 0956 I 3896 I 6681 : 044 - 2829 0956 : investor.relations@apollohospitals.com Apollo Hospitals Enterprise Limited Earnings Update Q4 FY25 • Disclaimer The information contained in this presentation is provided by Apollo Hospitals Enterprise Limited (the “Company”) to you solely for your reference.”

“You acknowledge that you will be solely responsible for your own assessment of the market and the market position of the Company and that you will conduct your own analysis and be solely responsible for forming your own view of the potential future performance of the business of the Company.”

“• Private and Generic Label sales at 17.4% (offline) for FY25.”

“in FY25, growth of 8% over FY24 Full stack digital healthcare platform • First-in-class AI enabled technologies including India’s first Clinical Intelligence Engine • Provides comprehensive remote healthcare services.”

“Expect to launch products with 12 insurers © 2025 Apollo Hospitals Enterprise Ltd, All Rights Reserved 9 • Consolidated Financials Consolidated Financials © 2025 Apollo Hospitals Enterprise Ltd, All Rights Reserved 10 Consolidated Financials Q4FY25 (` mio) Overall Consolidated Revenue grew by 13% to ` 55,922 mio.”

“' Clinics il),A ® Apollo Sugar Clinics ~.A Apollo DIAGNOSTICS ®  Core revenues of Primary Care grew by  Wellness segment volume grew by ~18% ~16% YoY in FY25, as a result of revamped health check plans and strengthening of corporate outreach  Improvement in margin profile primarily due to optimization of fixed costs  Preventive Health-checks volume grew by ~17% YoY in FY25  Plan to expand service offerings in Core Clinics – weight loss, joint preservation etc.”

“ Net addition of 10 Centres in Dialysis in FY25 YoY in FY25 & accounted ~19% of Diagnostics revenue (vs ~16% in FY24)  Continuous improvement in EBITDA margin over the past 2 years (~10% in FY25 vs ~6% in FY23)  110 tests started inhouse in FY25.”

“Added IC- PMS based heavy metal testing, culture identification, various cytogenetics related testing, microarray analysis to the portfolio in Q4 FY25  Existing business model of Franchisee modified into a more profitable model il)A e Apollo Soectra Specialists IHOSPITALS in Surgery ~lo Cradle &Children's Hospital ltollo Fertility  Spectra: ~19% YoY revenue growth in FY25 driven by operationalization of renovated centers.”

“Renovated Jaipur centre commissioned recently and is expected to increase revenue contribution in FY26  Cradle: ~12% YoY revenue growth in FY25.”

“gross realization per patient (INR)* Network Growth – Collection Centers # Operational footprint (as of March 31, 2025) ~330+ ~330+ ~330+ Cities Cities presence Cities presence presence 104 Labs 827 806 811 822 2,263 731 15,143 16,205 13,697 14,420 14,898 Q4 FY24 Q1 FY25 Footfalls / Day** Q2 FY25 Q3 FY25 Gross ARPV (Rs.) Q4 FY25 1.”

Digital Operational Metrics

2

Regd. Office

1

General Office

1

Omnichannel Healthcare Division

1

General Office

"Ali Towers" Ill Floor, #55, Greams Road, Chennai - 600 006. Tel Telefax Email Website : www.apollohospitals.com : 044 - 2829 0956 I 3896 I 6681 : 044 - 2829 0956 : investor.relations@apollohospitals.com Apollo Hospitals Enterprise Limited Earnings Update Q4 FY25 • Disclaimer The information contained in this presentation is provided by Apollo Hospitals Enterprise Limited (the “Company”) to you solely for your reference. This document is being given solely for your information and for your use and may not be retained by you and neither this presentation nor any part thereof may be (i) used or relied upon by any other party or for any other purpose; (ii) copied, photocopied, duplicated or otherwise reproduced in any form or by any means; or (iii) redistributed, passed on or otherwise disseminated, to any other person without the prior written consent of the Company. Although care has been taken to ensure that the information in this presentation is accurate, and that the opinions expres

Omnichannel Healthcare Division

o Omnichannel Pharmacy (AHL+ APL) Business revenue of Rs 30,401 Mn in Q4’ FY25 compared to a revenue of Rs. 25,876 Mn in Q4’ FY24 (growth of 17.5%). o Apollo Telehealth (under AHEL) Revenues of Rs.175 Mn in Q4FY25.

Digital Operational Metrics

o Platform GMV : Rs 7,954 Mn in Q4’ FY25, growth of 11% over Q4’ FY24 o New customer acquisition channel started to gain traction (launch of 19 mins & Omni Acquisition) o Continuous Improvement in quantitative parameters in Q4’ FY25 vs Q4’ FY24: o 25% YoY growth in Online Pharma Transactions. o DAU Mar exit shows YoY growth of 45% * Excluding 24|7 operating Cost and ESOP Non-Cash Charge Digital Cash loss* (in Mn) Q4'FY24 Q3'FY25 Q4'FY25 -1,108 -758 -798 222 Healthco Cash profit* (in Mn) 4X 835 819 Offline Segment 28% Q4'FY24 Q3'FY25 Q4'FY25 o 12.6% YoY growth in offline transactions (8.0 cr Vs 7.1 cr year back). *Cash loss/profit is EBITDA post Ind As excluding ESOP expense O Serving ~8.9 lac offline customers per day © 2025 Apollo Hospitals Enterprise Ltd, All Rights Reserved 31 ` MioOffline Pharmacy Distribution Online Pharmacy Distribution & Apollo 247Total HealthCoTotal Revenues20,8442,91923,763EBITDA (Pre 24|7 Cost)1,6163501,966margin (%) 7.8%12.0%8.3%24/7 Operating Cost-1,147-1,1

Digital Operational Metrics

Platform GMV : Rs 30,073 Mn in FY25, growth of 8% over FY24 Offline Segment o 12.6% YoY growth in offline transactions (30.8 cr Vs 27.4 cr year back). * Excluding 24|7 operating Cost and ESOP Non-Cash Charge © 2025 Apollo Hospitals Enterprise Ltd, All Rights Reserved 32 ` MioOffline Pharmacy Distribution Online Pharmacy Distribution & Apollo 247Total HealthCoTotal Revenues80,14310,78790,930EBITDA (Pre 24|7 Cost)6,1241,4097,533margin (%) 7.6%13.1%8.3%24/7 Operating Cost-4,781-4,781ESOP(Non Cash expense)-1,076-1,076EBITDA 6,124-4,4491,676margin (%) 7.6%-1.8%EBIT1,127PBT469PAT (Reported)469Total Revenues69,2689,00178,269EBITDA (Pre 24|7 Cost)5,2301,0296,260margin (%) 7.6%11.4%8.0%24/7 Operating Cost-6,186-6,186ESOP(Non Cash expense)-891-891EBITDA 5,230-6,047-817margin (%) 7.6%--EBIT-1,309PBT-1,956PAT (Reported)-1,957Revenue16%20%16%EBITDA (Pre 24|7 Cost)17%37%20%FY25FY24 Apollo HealthCo : Advent Investment - Tranche 1&2 of INR 2,475 crs completed • Apollo Healthco Limited (“AHL”) raised e